Zobrazeno 1 - 10
of 53
pro vyhledávání: '"R F, Jacobs"'
Autor:
S. M. Marcy, N. R. Rabinovich, N. E. MacDonald, R. F. Jacobs, Richard J. Whitley, Jon S. Abramson, Leonard B. Weiner, P. J. Chesney, Charles G. Prober, G. Peter, W. A. Orenstein, Michael A. Gerber, Dennis Murray, B. Schwartz, Robert F. Breiman, Thomas N. Saari, Larry K. Pickering, Gary D. Overturf, Neal A. Halsey, A. Hirsch, M. C. Hardegree, Carol J. Baker, Margaret C. Fisher
Publikováno v:
Pediatrics. 102:1483-1491
Virtually all children experience rotavirus (Rv) infection before school entry. In the United States and other temperate countries, Rv disease peaks in the winter and during this time is responsible for the majority of episodes of diarrhea in infants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1479ee8559220e8739788f61c2f20e56
https://doi.org/10.1542/peds.102.6.1483
https://doi.org/10.1542/peds.102.6.1483
Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children
Autor:
B J Ewing, Michael D. Reed, W M Gooch, R F Jacobs, K Willims, G L Kearns, Jeffrey L. Blumer, Ram Yogev
Publikováno v:
Antimicrobial Agents and Chemotherapy. 39:1721-1725
Meropenem is a new carbapenem antibiotic which possesses a broad spectrum of antibacterial activity against many of the pathogens responsible for pediatric bacterial infections. In order to define meropenem dosing guidelines for children, an escalati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92dc2d4f5a0840b5fdea2c2362f43e5b
https://doi.org/10.1128/aac.39.8.1721
https://doi.org/10.1128/aac.39.8.1721
Publikováno v:
Infection. 21:279-290
Despite widespread advances in intensive care practices, and more potent and effective antimicrobials, septic shock continues to have a mortality rate of greater than 40%. Although antimicrobials can treat the etiologic organism, they do not alter th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cf7f2b610bdabecbec0fc271ad06bca
https://doi.org/10.1007/bf01712446
https://doi.org/10.1007/bf01712446
Autor:
R. F. Jacobs
Publikováno v:
Infection. 19:S330-S336
The utilization of cephalosporins in serious bacterial infections in children has become more widely accepted by pediatric infectious disease specialists over the past five years. The use of cephalosporins has become increasingly popular in empiric a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b8862f65ad6e1bf0962541d6920cdd2
https://doi.org/10.1007/bf01715774
https://doi.org/10.1007/bf01715774
Publikováno v:
The Pediatric Infectious Disease Journal. 17:439-441
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::869b68bb395833f4da7e32d7d9367dac
https://doi.org/10.1097/00006454-199805000-00025
https://doi.org/10.1097/00006454-199805000-00025
Autor:
A M, Prince, R F, Jacobs
Publikováno v:
The Journal of the Arkansas Medical Society. 98(4)
The incidence of serious RSV illness in premature infants and in infants with CLD can be reduced. Prophylaxis in infants with CHD and cystic fibrosis seem prudent as well, and clinical trials are currently under way to evaluate the use of Synagis in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4c82c3d6d3910d966e542be482bd4fee
https://pubmed.ncbi.nlm.nih.gov/11594047
https://pubmed.ncbi.nlm.nih.gov/11594047
Publikováno v:
Archives of pediatricsadolescent medicine. 155(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::38bac85e9f4e711ede87c4bc458a4021
https://pubmed.ncbi.nlm.nih.gov/11483128
https://pubmed.ncbi.nlm.nih.gov/11483128
Autor:
G L, Kearns, S M, Abdel-Rahman, J L, Blumer, M D, Reed, L P, James, R F, Jacobs, J A, Bradley, I R, Welshman, G L, Jungbluth, D J, Stalker
Publikováno v:
The Pediatric infectious disease journal. 19(12)
Background Linezolid is an oxazolidinone antibiotic with excellent in vitro activity against a number of Gram-positive organisms including antibiotic-resistant isolates. The safety and pharmacokinetics of intravenously administered linezolid were eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::849e454eda3de766b71fb543e02f824d
https://pubmed.ncbi.nlm.nih.gov/11144380
https://pubmed.ncbi.nlm.nih.gov/11144380
Single dose pharmacokinetics of pleconaril in neonates. Pediatric Pharmacology Research Unit Network
Autor:
G L, Kearns, J S, Bradley, R F, Jacobs, E V, Capparelli, L P, James, K M, Johnson, S M, Abdel-Rahman
Publikováno v:
The Pediatric infectious disease journal. 19(9)
Pleconaril is an orally active, broad spectrum antipicornaviral agent with activity against nonpolio enteroviruses. Pleconaril phamacokinetics was evaluated in 16 neonates (16.4 +/- 8.7 days postnatal age) with suspected enteroviral infection.Plecona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::13d47a3eaa7052a095658eb3ace2e8ca
https://pubmed.ncbi.nlm.nih.gov/11001105
https://pubmed.ncbi.nlm.nih.gov/11001105
Publikováno v:
Archives of pediatricsadolescent medicine. 154(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cda04b49b960891657f2e57cf17bf111
https://pubmed.ncbi.nlm.nih.gov/10710035
https://pubmed.ncbi.nlm.nih.gov/10710035